• Arobella Medical (Minneapolis) said that it has launched the Qoustic Wound Therapy System, which advances the use of low-frequency cavitational ultrasound for wound care, offering “an alternative to painful sharps debridement and other surgical modalities.” The Qoustic assists healing by gently removing dead or diseased tissue cells and bacteria, leaving healthy and pre-healing granulation tissue intact and is also useful in preparing the wound bed for other therapies, such as grafts and flaps. Low-frequency ultrasound debridement is emerging as a preferred method of care for many types of wounds, including pressure ulcers, diabetic ulcers, infected wounds, burns and other chronic wounds. The system’s dome-shaped Qoustic Qurette vibrates at 35 kHz, converting electrical energy to ultrasound waves and focusing them intensively on the wound. Sterile saline solution transfers the ultrasonic energy to the wound, where tiny vibrating gas bubbles and cellular-level fluid movement separate dead and harmful cells from healthy tissue. Arobella makes low-frequency ultrasound products.

• The Aurora Breast MRI Society (North Andover, Massachusetts) previewed the newly developed Aurora Breast MRI Society Global PACS Teaching Tool before an audience of more than 100 radiology professionals in attendance at the second annual Aurora Breast MRI Society Meeting. Unlike traditional PACS formats, the Teaching Tool will be the first PACS platform that will be exclusively used by a professional group, Aurora said. Members will be able to upload clinical cases and images without disclosing private patient information, interact with colleagues and extract images as needed to digitally exchange best practices and clinical knowledge, thus building a global Internet-based community for Aurora Breast MRI Society healthcare professionals to share experiences and insights. Aurora Breast MRI Society is a group of dedicated breast radiologists committed to advancing breast MRI technology.

• Concordia Medical (Coventry, Rhode Island) reported the first clinical uses of Biofelt, a non-woven biomaterial which can readily be absorbed by the human body. Concoridia said that two of its medical device customers have separately received approvals to proceed with human clinical uses of products based on Biofelt in the urological and dental implant markets. Biofelt, a bioabsorbable polymer fiber scaffold that is porous, soft and flexible, biocompatible and enables human cells to grow into its 3-D interconnected pores so that new natural tissue can be formed to replace and/or repair damaged human tissues. Biofelt has been used in numerous leading biomedical research laboratories around the world for various advanced tissue engineering applications in the field of regenerative medicine. Biofelt is produced from medical grade polyglycolic acid and poly-L lactic acid and can be formed into various size sheets, discs, and tubes. Thicknesses can be specified from 0.3 to 7 mm and the bulk density from 30 to 300 mg/cc. Finished scaffolds are scoured, vacuum-sealed in moisture barrier foil pouches and packed with desiccant. Concordia Medical makes fiber based medical implants and scaffolds for regenerative medicine.